{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "PARK7 M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 3a: Basic Controls and Replicates.",
          "extracted_paper_info": "TTRAP protected neuroblastoma cells from apoptosis induced by proteasome impairment. In these conditions, endogenous TTRAP relocalized to a detergent-insoluble fraction and formed cytoplasmic aggresome-like structures. Interestingly, both DJ-1 mutants blocked the TTRAP protective activity unmasking a c-jun N-terminal kinase (JNK)- and p38-MAPK (mitogen-activated protein kinase)-mediated apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper details a functional assay (protection from proteasome-induced apoptosis) with a clear comparison between wild-type and mutant DJ-1. While not explicitly mentioned, the description suggests a control of the neuroblastoma cells being treated with proteasome impairment without TTRAP and with wild-type DJ-1, allowing for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses.",
          "extracted_paper_info": "The paper describes that 'both DJ-1 mutants blocked the TTRAP protective activity', implying a difference between wild-type and mutant DJ-1 in their ability to confer protection. The study doesn't report oddsPath or similar statistical analysis",
          "judgment": "No",
          "reasoning": "The data is descriptive, indicating an effect, but without reported statistical values that can be used to quantitatively assess effect size",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation.",
          "extracted_paper_info": "The description doesn’t provide the number of benign/pathogenic variants controls in the study.",
          "judgment": "N/A",
          "reasoning": "Because there's no data on variant controls available, this step cannot be used to strengthen or weaken the evidence.",
          "next_step_or_outcome": "Final Strength Assignment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The M26I mutation in PARK7 blocks the protective effect of TTRAP against proteasome-induced apoptosis in neuroblastoma cells, however, without quantitative oddsPath, the evidence is not as strong as PS3 moderate/very strong, thus classified as PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "PARK7 L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 3a: Basic Controls and Replicates.",
          "extracted_paper_info": "TTRAP protected neuroblastoma cells from apoptosis induced by proteasome impairment. In these conditions, endogenous TTRAP relocalized to a detergent-insoluble fraction and formed cytoplasmic aggresome-like structures. Interestingly, both DJ-1 mutants blocked the TTRAP protective activity unmasking a c-jun N-terminal kinase (JNK)- and p38-MAPK (mitogen-activated protein kinase)-mediated apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper details a functional assay (protection from proteasome-induced apoptosis) with a clear comparison between wild-type and mutant DJ-1. While not explicitly mentioned, the description suggests a control of the neuroblastoma cells being treated with proteasome impairment without TTRAP and with wild-type DJ-1, allowing for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses.",
          "extracted_paper_info": "The paper describes that 'both DJ-1 mutants blocked the TTRAP protective activity', implying a difference between wild-type and mutant DJ-1 in their ability to confer protection. The study doesn't report oddsPath or similar statistical analysis",
          "judgment": "No",
          "reasoning": "The data is descriptive, indicating an effect, but without reported statistical values that can be used to quantitatively assess effect size",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation.",
          "extracted_paper_info": "The description doesn’t provide the number of benign/pathogenic variants controls in the study.",
          "judgment": "N/A",
          "reasoning": "Because there's no data on variant controls available, this step cannot be used to strengthen or weaken the evidence.",
          "next_step_or_outcome": "Final Strength Assignment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The L166P mutation in PARK7 blocks the protective effect of TTRAP against proteasome-induced apoptosis in neuroblastoma cells, however, without quantitative oddsPath, the evidence is not as strong as PS3 moderate/very strong, thus classified as PS3_supporting."
    }
  ]
}